Construction of Macaque Immune-Libraries

Area of Science:

• Biotechnology
• Immunology
• Pharmacology

Background:

• The first therapeutic antibodies, derived from murine hybridoma technology, showed clinical success but caused immunogenicity and anti-drug antibody (ADA) responses in patients.
• The nonhuman origin of murine antibodies can lead to accelerated drug elimination or severe adverse reactions like anaphylaxis upon repeated administration.
• Subsequent generations of therapeutic antibodies (chimeric, humanized, fully human) were developed through molecular engineering to improve patient tolerance.

Purpose of the Study:

• To present a strategy for constructing macaque antibody immune libraries.
• To enable the isolation of high-affinity and well-tolerated engineered antibodies.
• To overcome limitations of murine antibody-based therapies when patient immunization is not feasible.

Main Methods:

• Utilizing phage-display screening of immune libraries derived from immunized nonhuman primates.
• Leveraging the phylogenetic proximity of macaques to humans for better antibody compatibility.
• Developing molecular engineering approaches to enhance antibody characteristics.

Main Results:

• Demonstrated a viable strategy for creating macaque antibody immune libraries.
• Established a method for isolating engineered antibodies with improved therapeutic potential.
• Provided a pathway to circumvent immunogenicity issues associated with murine antibodies.

Conclusions:

• Macaque antibody immune libraries are a valuable tool for generating next-generation therapeutic antibodies.
• Phage-display technology combined with nonhuman primate libraries offers a promising approach to overcome antibody immunogenicity.
• This strategy facilitates the development of safer and more effective antibody-based therapeutics.